<乌鸦传媒>Genetic Role of Alcohol-Cancer Link Strengthened In study from China, two common variants associated with lower risk of cancer in men Feb 01, 2022
<乌鸦传媒>When Strangers Deliver Bad News to Patients All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
<乌鸦传媒>Dual HER2 Therapy Active in Previously Treated Lung Cancer Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
<乌鸦传媒>An 'Intriguing Failure' in Advanced, Pre-Treated GIST Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
<乌鸦传媒>Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
<乌鸦传媒>Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
<乌鸦传媒>GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
<乌鸦传媒>Adagrasib Promising in KRAS-Mutant GI Cancers The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
<乌鸦传媒>Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
<乌鸦传媒>Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRC No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab Jan 23, 2022
<乌鸦传媒>Potential New First-Line Options for Unresectable Hepatocellular Carcinoma Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
<乌鸦传媒>Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer Jan 21, 2022
<乌鸦传媒>More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression Jan 21, 2022
<乌鸦传媒>We've Never Really Understood the Prostate Wolinsky reviews Ericka Johnson's new book, A Cultural Biography of the Prostate Jan 19, 2022
<乌鸦传媒>Growing Controversy Over 'Skinny' Labeling for Generic Drugs What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
<乌鸦传媒>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<乌鸦传媒>Earlier Colorectal Screening Bolstered by Real-World Data Researchers of a national registry study say "45 is now the new 50" Jan 10, 2022
<乌鸦传媒>Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<乌鸦传媒>Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiation Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
<乌鸦传媒>Finally, a 'New Standard' for Severe Aplastic Anemia After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
<乌鸦传媒>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<乌鸦传媒>In Early Prostate Cancer, Black Men Do Better With Radiotherapy Than White Men "Unexpected" finding holds even though Black men are more likely to have high-risk features Dec 29, 2021
<乌鸦传媒>Living History: 50 Years After the Birth of National Cancer Centers New book examines the progress 50 years following the National Cancer Act of 1971 Dec 22, 2021
<乌鸦传媒>Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer No improvement in PFS versus standard for older patients ineligible for intensive therapy Dec 21, 2021
<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<乌鸦传媒>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<乌鸦传媒>Virgil Abloh's Cardiac Angiosarcoma The fashion designer's death due to this rare form of cancer took the world by surprise Dec 15, 2021
<乌鸦传媒>Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<乌鸦传媒>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<乌鸦传媒>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<乌鸦传媒>In the Story of Our Practice, We're Always the Hero When is it right to challenge our medical colleagues? Dec 14, 2021
<乌鸦传媒>R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<乌鸦传媒>尾-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<乌鸦传媒>R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<乌鸦传媒>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
